Completed PHASE4 INTERVENTIONAL 2-arm NCT00929279

Efficacy of Abciximab Bolus Only Regimen in Providing Inhibition of Platelet Action Over Time (FABOLUS)

Facilitation Through Abciximab By drOpping Infusion Line in Patients Undergoing Coronary Stenting. SYNergy With Clopidogrel at High Loading dOse Regimen

Sponsor: Università degli Studi di Ferrara

Conditions Acute Coronary Syndrome

Interventions abciximab bolus only regimen bolus+infusion

Updated 4 times since 2017 Last updated: Jun 26, 2009 Started: Nov 30, 2008 Primary completion: May 31, 2009 Completion: May 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00929279, this PHASE4 trial focuses on Acute Coronary Syndrome and remains completed. Sponsored by Università degli Studi di Ferrara, it has been updated 4 times since 2008, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2017 — Jan 2021 [monthly]

Completed PHASE4

First recorded

Nov 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Università degli Studi di Ferrara

Data source: Università degli Studi di Ferrara

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ferrara, Italy